NeuroPace RNS System
NeuroPace, Inc. · Decision date Aug 19, 2026
What did the FDA decide?
FDA records P100026/S104 as a supplement to PMA P100026, with the supplement type “30-Day Notice”. The recorded decision is OK30 (30-day notice), dated Aug 19, 2026.
FDA approval order statement
to remove an in-process screening test used in the manufacture of the RNS-320 Neurostimulators
- Regulatory pathway
- PMA supplement
- Supplement type
- 30-Day Notice
- Clinical specialty
- Neurology
- Decision date
- Aug 19, 2026
- FDA change category
- Process Change - Manufacturer/Sterilizer/Packager/Supplier
Regulatory record facts
- Identifier
- P100026/S104
- Regulatory pathway
- PMA supplement
- Applicant
- NeuroPace, Inc.
- Product code
- PFN
- Decision code
- OK30
- Decision date
- Aug 19, 2026
- Source update
- Nov 9, 2026
- Original record
- Open FDA source record
About this medical device
FDA device category: Implanted brain stimulator for epilepsy.
- Applicant
- NeuroPace, Inc.
- Product code
- PFN
- FDA device class
- 3
Review the original FDA PMA listing for the original approval scope and linked supplements.
FDA decision timeline
P100026/S099 · Related supplement
NeuroPace RNS System
P100026/S103 · Related supplement
NeuroPace RNS System
P100026/S101 · Related supplement
NeuroPace RNS System
P100026/S100 · Related supplement
NeuroPace RNS System
P100026/S104 received
Application receipt date recorded by FDA.
P100026/S104 · FDA decision
30-Day Notice
Timeline entries are records held by MedtechLedger for P100026. View FDA’s full supplement list.
Related devices and submissions
Same PMA: P100026
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
NeuroPace RNS SystemP100026/S099 | NeuroPace, Inc. | PMA supplement | Aug 18, 2025 | FDA |
NeuroPace RNS SystemP100026/S103 | NeuroPace, Inc. | PMA supplement | Feb 20, 2026 | FDA |
NeuroPace RNS SystemP100026/S101 | NeuroPace, Inc. | PMA supplement | May 28, 2026 | FDA |
NeuroPace RNS SystemP100026/S100 | NeuroPace, Inc. | PMA supplement | Jun 17, 2026 | FDA |
Regulatory context
A PMA supplement records a change to a device with an existing premarket approval. The supplement’s approval applies to the change described in that submission.
Read our guide to FDA clearance and approval · FDA’s explanation of this pathway
Manufacturer intelligence
NeuroPace, Inc.
- Headquarters
- Not reported
- Brand website
- Not reported
- FDA applicant address
- 455 N Bernardo Ave., Mountain View, CA, 94043
Sources and methodology
- Original FDA record: P100026/S104
- openFDA source data · Source release Nov 9, 2026 · Retrieved Nov 20, 2026
FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.
How we use FDA records